MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of “Hold” from Analysts

MacroGenics, Inc. (NASDAQ:MGNX) has been given a consensus rating of “Hold” by the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $3.60.

MGNX has been the topic of a number of research analyst reports. Zacks Research downgraded MacroGenics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of MacroGenics in a research note on Monday, November 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MacroGenics in a research note on Monday, December 22nd.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Leonteq Securities AG purchased a new stake in MacroGenics in the 4th quarter valued at approximately $161,000. GSA Capital Partners LLP raised its holdings in shares of MacroGenics by 740.5% in the fourth quarter. GSA Capital Partners LLP now owns 511,004 shares of the biopharmaceutical company’s stock worth $823,000 after acquiring an additional 450,203 shares during the last quarter. AlphaCore Capital LLC purchased a new stake in shares of MacroGenics in the fourth quarter valued at $61,000. R Squared Ltd acquired a new stake in shares of MacroGenics during the fourth quarter valued at $26,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of MacroGenics by 42.9% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 300,000 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 90,000 shares during the last quarter. 96.89% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Trading Up 6.5%

Shares of MGNX opened at $1.81 on Monday. MacroGenics has a twelve month low of $0.99 and a twelve month high of $2.95. The firm has a market capitalization of $114.50 million, a P/E ratio of -1.51 and a beta of 1.50. The firm’s 50-day moving average is $1.64 and its two-hundred day moving average is $1.64.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.75. The company had revenue of $72.84 million during the quarter, compared to the consensus estimate of $28.72 million. MacroGenics had a negative net margin of 59.46% and a negative return on equity of 98.30%. Analysts predict that MacroGenics will post -1.06 EPS for the current year.

MacroGenics Company Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody–based therapeutics for the treatment of cancer and autoimmune diseases. The company leverages proprietary Fc engineering technologies to enhance immune engagement and extend the activity of its antibodies. Since its founding in 2000, MacroGenics has advanced several product candidates through clinical trials, most notably margetuximab, a HER2-targeted antibody designed to improve outcomes in patients with HER2-positive breast cancer.

Central to MacroGenics’ research platform are its ADAPTIR and Trident bispecific antibody technologies.